Stayble Therapeutics AB (publ) (FRA:4K4)

Stayble Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-23.74	-24.53	-12.09	-15.49
Other Operating Activities	0.19	-0.26	-0.08	0.17
Change in Accounts Receivable	-1.32	-0.13	0.96	-1.23
Change in Other Net Operating Assets	1.33	0.03	1.58	-7.43
Operating Cash Flow	-23.54	-24.89	-9.63	-23.98
Investment in Securities	-	-	-0	-
Investing Cash Flow	-	-	-0	-
Long-Term Debt Issued	-	0	-	-
Long-Term Debt Repaid	-	-	-0.19	-0.14
Net Debt Issued (Repaid)	-	0	-0.19	-0.14
Issuance of Common Stock	31.82	-	41.54	35.14
Other Financing Activities	-6.85	-	-5.19	-3.81
Financing Cash Flow	24.96	0	36.15	31.19
Foreign Exchange Rate Adjustments	-0.19	0.26	0.08	-0.17
Net Cash Flow	1.23	-24.62	26.6	7.04
Levered Free Cash Flow	-15.08	-15.71	-5.09	-18.11
Unlevered Free Cash Flow	-15.06	-15.69	-5.05	-17.86
Change in Working Capital	0.01	-0.1	2.54	-8.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.